|
Clinical features
|
N (%)
|
Survival
|
|---|
|
1 yr.(%)
|
2 yrs. (%)
|
p
|
|---|
|
Gender
|
|
Male
|
88 (76.52)
|
63.67
|
38.98
| |
|
Female
|
27 (23.48)
|
62.96
|
57.89
|
0.523
|
|
Age (y.o)
|
|
<60
|
37 (32.17)
|
56.76
|
29.63
| |
| ≧60 |
78 (74.26)
|
66.67
|
45.28
|
0.207
|
|
ECOG
|
|
0
|
49 (42.61)
|
75.51
|
54.29
| |
|
1
|
53 (46.09)
|
58.49
|
36.36
| |
|
2
|
13 (11.3)
|
46.15
|
20
|
0.118
|
|
Child-Pugh score
|
|
A
|
104 (90.43)
|
68.27
|
47.14
| |
|
B
|
11 (9.57)
|
27.27
|
12.5
|
<0.001
|
|
AJCC stage (7th)
|
|
I
|
21 (18.26)
|
85.71
|
78.57
| |
|
II
|
18 (15.65)
|
72.22
|
60
| |
|
IIIA
|
26 (22.61)
|
69.23
|
40
| |
|
IIIB
|
27 (23.48)
|
37.03
|
11.11
| |
|
IIIC
|
3 (2.61)
|
100
|
0
| |
|
IV
|
20 (17.39)
|
55
|
37.5
|
0.001
|
|
BCLC
|
|
A
|
12 (10.44)
|
83.33
|
75
| |
|
B
|
23 (20)
|
86.26
|
56.25
| |
|
C
|
80 (69.56)
|
55
|
31.48
|
0.080
|
|
Tumor type
|
|
Solitary
|
38 (33.04)
|
81.58
|
62.5
| |
|
Multiple
|
69 (60)
|
56.52
|
31.25
| |
|
Diffuse
|
8 (6.96)
|
37.5
|
33.33
|
<0.001
|
|
Tumor site
|
|
Right
|
91 (79.13)
|
64.83
|
42.86
| |
|
Left
|
14 (13.04)
|
53.33
|
38.46
| |
|
Bilateral
|
10 (8.7)
|
60
|
0
|
0.506
|
|
Max. tumor diameter (cm)
|
| ≦4 |
40 (34.78)
|
75
|
55.17
| |
|
> 4-9
|
47 (40.87)
|
68.82
|
36.67
| |
| ≧10 |
28 (23.48)
|
48.15
|
26.32
|
0.187
|
|
Portal vein tumor thrombosis
|
|
Yes
|
34 (29.56)
|
35.29
|
12
| |
|
No
|
81 (70.43)
|
75.31
|
53.7
|
<0.001
|
|
Hepatitis virus
|
|
B
|
59 (51.3)
|
66.1
|
36.58
| |
|
C
|
42 (36.52)
|
59.52
|
46.43
| |
|
Non B non C
|
11 (9.57)
|
81.82
|
77.78
| |
|
B + C
|
3 (2.61)
|
66.67
|
0
|
0.576
|
|
AFP Level (ng/ml)
|
| ≦20 |
41 (34.78)
|
82.93
|
62.5
| |
|
> 20-400
|
31 (27.84)
|
51.61
|
17.65
| |
| ≧400 |
43 (37.39)
|
53.49
|
34.48
|
0.013
|
|
Biochemical changes
|
|
Albumin (g/dl) [N = 109]
|
|
<3.5
|
26 (23.85)
|
46.15
|
31.81
| |
|
≥3.5
|
83 (76.15)
|
67.47
|
44.64
|
0.027
|
|
Alkaline Phosphatase (IU/L) [N = 104]
|
| ≧129 |
37 (35.58)
|
59.45
|
42.57
| |
|
<129
|
67 (64.42)
|
64.18
|
36.95
|
0.893
|
|
Platelet (10^3/uL) [N = 109]
|
|
<150
|
52 (47.71)
|
63.46
|
35
| |
| ≧150 |
57 (52.29)
|
68.42
|
48.65
|
0.291
|
|
BED
|
| ≦72 Gy10 |
65 (56.52)
|
56.92
|
28.2
| |
|
73-88 Gy10
|
8 (6.96)
|
62.5
|
28.57
| |
| ≧89 Gy10 |
42 (36.52)
|
76.19
|
56.25
|
0.038
|
|
Previous treatment
|
|
Yes
|
52 (45.22)
|
50
|
37.14
| |
|
No
|
63 9(54.78)
|
55.56
|
43.18
|
0.584
|
- Abbreviations: ECOG Eastern Cooperative Oncology Group, AJCC American Joint Cancer Conference, BCLC Barcelona Clinic Liver Cancer Stage, AFP Alpha-Feto Protein, BED Biological Effective Dose
